Beyond Cancer Presents Positive Preclinical Data for Ultra-High Concentration Nitric Oxide (UNO) in Combination with Checkpoint Inhibitor Therapy During the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

50,000 or 100,000 ppm UNO alone or in combination with anti-mCTLA-4 more than tripled antigen specific central memory T-cell response versus anti-mCTLA-4 alone

Pooled analysis of combination studies of 50,000 or 100,000 ppm UNO with anti-mPD-1 demonstrated more than a doubling in survival at Day 75 versus anti-mPD-1 alone

Initial data from a Phase 1a, first-in-human study to be presented at the Society for Immunotherapy in Cancer (SITC) on November 3, 2023

GARDEN CITY, N.Y. and HAMILTON, Bermuda, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, today announced promising new preclinical data further supporting the company’s novel UNO therapy for various types of solid tumors as a single agent and in combination with checkpoint inhibitors. These data were presented in two posters at the American Association for Cancer Research-National Cancer Institute-European Organisation for Research and Treatment of Cancer (AACR-NCI-EORTC) International Conference on Molecular Targets and Cancer Therapeutics 2023, which was held October 11^th – 15^th in Boston, Massachusetts. Full abstracts and posters are available on the company’s website (click here).

“With today’s data we continue to further elucidate the mechanism by which UNO demonstrates synergy with checkpoint inhibitors,” stated Dr. Selena Chaisson, Chief Executive Officer and Director of Beyond Cancer. “We further quantified the extent of the synergy seen with the combination of UNO and checkpoint inhibitors by using a meta-analysis of the data in a large body of work. Data from this analysis are exciting additions to the growing body of evidence supporting UNO as a potential therapeutic option for cancer patients. We look forward to the initial data from our first-in-human Phase 1a study later this year.”

Abstract #: 35782 describes a pooled analysis of preclinical studies utilizing 50,000 or 100,000 ppm UNO for 5 or 10 minutes in combination with 4-5 doses of 5 or 10 mg/kg Anti-mPD-1. The analysis showed that the combination therapy resulted in statistically significant primary and secondary tumor-free mice at day 75 compared with mice treated with anti-mPD-1 alone (p=0.02). In addition, the analysis showed a statistically significant improvement in survival during the same time period (p=0.0038).